Finally, the applicant stated that, under the regulation at 419.66(a), CMS makes a pass-through payment for a medical device that meets the requirements in paragraph (b) of that section and that is described by a category of devices established by CMS under the criteria in paragraph (c) of that section, and that, further, according to 419.66(g), the pass-through period begins on the first date on which pass-through payment is made
This therapy is being studied for conditions ranging from joint injuries to gut inflammation, showing early promise in multiple domains
Three things make PDRN a strong alternative for users disappointed by copper peptides: It signals regeneration through a different pathway, so it does not produce the same inflammatory adjustment phase that drives the copper uglies It has fewer documented interactions with other actives, which makes it easier to fit into an existing routine It is generally well tolerated even by sensitive skin, and pregnancy precautions are less restrictive (though pregnant or breastfeeding users should still consult a doctor before adding any new active) The people who tend to do well on PDRN after a bad copper peptide experience usually fit one of three profiles: sensitive-skin users who could never tolerate the copper uglies, users who want regenerative benefits without managing strict layering rules, and users whose primary concern is repair and resilience rather than aggressive remodelling
M.XiongT
